January 6, 2021
Mind Cure, a Canadian mental health company, has released a digital therapeutic tool designed to close the gaps between patients, clinicians and researchers.
Called iSTRYM, the app provides close to real-time data regarding patient care, procedures and protocols. It’s described as a centralized management system that can be used for a variety of mental health treatments, including those in...
December 14, 2020
Bold Health, a London-based company developing digital therapeutics for gastrointestinal conditions, is backing a new University of Pennsylvania-led study that will directly compare the company's cognitive behavior therapy (CBT) app for irritable bowel syndrome (IBS) to Headspace's consumer mindfulness and meditation app.
According to a clinicaltrials.gov listing spotted by Exits & Outcomes,...
November 9, 2020
The FDA granted Minneapolis-based NightWare a De Novo clearance on Friday for its Apple Watch and iPhone app designed to improve the sleep quality of those experiencing nightmare disorder and nightmares related to PTSD.
The digital therapeutic – which received breakthrough designation from the agency last year – uses the Watch's sensors to track the heart rate and movement of users as they sleep...
July 13, 2020
Swedish pharma company Orexo is jumping into the American digital-therapeutics game with the announcement of two new products, deprexis for treating depression symptoms and vorvida, a treatment for problematic alcohol use.
The new treatments are coming to the US market thanks to relaxed FDA regulations surrounding digital health products for psychiatric disorders, which was enacted as a result...
June 29, 2020
Nordic digital therapeutics company SidekickHealth is partnering with pharma giant Pfizer to launch a digital therapeutics platform, in a deal thought to be worth more than $8 million.
The solution combines scientific expertise and digital technologies, giving patients a tool to help them maintain healthy lifestyles and improve their disease management and quality of life, while providing...
May 6, 2020
Digital mental health company Limbix scored $9 million in Series A funding. The new round was led by GSR Ventures with participation from sequoia Capital, Storm Ventures, NexGen Venture Partners and BIXINK Therapeutics.
This comes roughly four months after the Palo Alto-based startup was selected as one of 27 digital health companies in MassChallenge HealthTech’s 2020 accelerator class.
December 12, 2019
A video game-like digital therapy may be key to helping reduce cognitive impairments in adults living with major depressive disorder (MDD).
Results out of a new study conducted by Akili interactive found that patients using the company’s AKL-T03 significantly improved their sustained attention compared to their peers in the control group.
In the study, which was presented at the Meeting of the...
September 27, 2019
It’s been two years since the first software-only digital therapeutic got the FDA greenlight, but the industry is still very much in its infancy and continuing to evolve. New entrances are emerging from the world of health, pharma, tech and finance. As the industry matures, it's grappling with existential questions including regulation, reimbursement models and, as always, the definition of a...
September 25, 2019
There’s no denying that digital therapeutics look and feel different than traditional medications. Instead of popping open a medication bottle, users are logging into an app to access treatment. But the differences don’t stop at the look. While the risk of toxicity is an ever-looming question in the pharma space, the same isn’t true for digital solutions.
Stakeholders at the digital therapeutics...
August 6, 2019
Paris, France-based Voluntis has received FDA marketing authorization for an algorithm-driven digital tool that helps cancer patients manage their symptoms and care teams identify clinical insights, the company announced last week.
The Oleena software is a Class II medical device that is prescribed by the patient’s care team. As the user logs their symptoms into the app, it adapts to offer...